Theratechnologies Inc. (THTX) has been issued U.S. Patent No. 10,799,562 by the United States Patent and Trademark Office (USPTO). The patent is directed to the treatment of Nonalcoholic Steatohepatitis (NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) in patients using tesamorelin.
This patent, which is scheduled to expire in 2040, stems from a patent application filed in March 2020 by Massachusetts General Hospital (MGH). Theratechnologies has an exclusive license with MGH to this patent.
The company submitted a phase 3 study protocol to the U.S. FDA in early September 2020, with the aim of beginning clinical trial in 1Q-2021.
Theratechnologies intends to use a new investigational formulation of tesamorelin, known as “F8”, for the conduct of such Phase 3 clinical trial. The Company is also working on the development of a convenient, multi-dose pen injector using the F8 formulation.